Back to today’s briefing

Story perspectives

FDA Review Sparks Debate Over Mifepristone's Safety in Abortions

5/24/2025

26 2

Summary

Story summary

At Glenwood Springs’ Planned Parenthood, over 70% of abortions rely on mifepristone and misoprostol. However, a new FDA review raises concerns, citing a contentious report that suggests serious complications from mifepristone in more than 10% of cases. Experts strongly challenge this claim, highlighting the drug's proven safety for over 5 million U.S. patients since 2000.

1 of 1

Story summary

At Glenwood Springs’ Planned Parenthood, over 70% of abortions rely on mifepristone and misoprostol. However, a new FDA review raises concerns, citing a contentious report that suggests serious complications from mifepristone in more than 10% of cases. Experts strongly challenge this claim, highlighting the drug's proven safety for over 5 million U.S. patients since 2000.